Core Viewpoint - Chongqing Shunbo Aluminum Alloy Co., Ltd. received a corrective measure order from the Chongqing Securities Regulatory Bureau, requiring the company to submit a written rectification report within 30 days due to issues related to financial reporting accuracy [1][2]. Group 1: Issues Identified - In 2024, the company recognized some revenue inappropriately across periods, leading to inaccurate financial reporting [2]. - The assessment of the net realizable value for inventory was unreasonable, resulting in insufficient provision for inventory impairment [2]. - The company did not adequately consider the credit risk of certain receivables, leading to insufficient provision for bad debts [2]. Group 2: Rectification Measures - The company has developed and improved financial accounting systems to enhance the quality of financial information, including guidelines for revenue recognition and inventory management [3]. - Training sessions have been organized for directors and senior management to improve compliance awareness and understanding of relevant accounting standards [5][6]. - The company plans to correct accounting errors related to the identified issues and will hold board meetings to address these corrections by April 2026 [7]. Group 3: Accountability and Summary - The chairman, president, and financial director are responsible for the rectification measures, and accountability procedures have been initiated for those responsible for the inaccuracies [8][9]. - The company views the issues raised in the corrective measure order as an opportunity to enhance its financial management and internal controls, aiming for improved transparency and governance [9].

Core Viewpoint - Fulin Precision (300432.SZ) has been reprimanded by the Sichuan Securities Regulatory Bureau for issues related to the disclosure of related party transactions, raising concerns about the effectiveness and stability of its internal controls [2][3][4]. Disclosure Issues - Fulin Precision has been found to have delayed and inaccurate disclosures regarding related party transactions, including the failure to disclose a special report on the use of raised funds for the first half of 2022 [3][4]. - The company previously received a warning in September 2021 for similar disclosure issues, where it failed to identify and disclose its relationship with Mianyang Anda Construction Engineering Co., Ltd. in its annual reports from 2018 to 2020 [4]. Financial Reporting Irregularities - The company has been cited for various financial accounting irregularities, including misreported revenue from outsourced processing materials and improper revenue recognition for some export businesses [5][6]. - These irregularities resulted in a misreported revenue of 12.45 million yuan, accounting for 0.15%, and a profit misreporting of 1 million yuan, accounting for 0.25% in the 2024 annual report [6]. Governance and Internal Control Issues - Fulin Precision has faced governance issues, such as missing votes from individual board members in some resolutions and lack of signatures from insiders on confidential information records [6]. - The Sichuan Securities Regulatory Bureau has mandated corrective administrative measures and issued warnings to key executives, including the chairman and general manager [6]. Strategic Developments - Prior to the regulatory measures, Fulin Precision announced plans to introduce CATL as a strategic investor through a private placement, with CATL being a significant customer for its lithium iron phosphate materials [7]. - The impact of the recent regulatory actions on the progress of this strategic investment remains uncertain, particularly regarding the company's related party transaction approval processes [7].

Core Viewpoint - Longsoft Technology (688078.SH) has received a corrective order from the Beijing Securities Regulatory Bureau due to irregularities in revenue and cost accounting, as well as accounts receivable management [1][2]. Group 1: Regulatory Actions - The company has been ordered to correct its accounting practices and has received warning letters for key executives, including Chairman Mao Shanjun, General Manager Ji Yangrui, and CFO Guo Junying [1][2]. - The violations include improper revenue recognition and cost allocation, which do not comply with relevant accounting standards [2]. Group 2: Financial Performance - Longsoft Technology's 2025 annual performance forecast indicates expected revenue between 148 million and 164 million yuan, with projected net losses ranging from 49 million to 60 million yuan [3]. - The company's 2024 annual report shows total revenue of 329 million yuan, a year-on-year decline of 17.04%, and a net profit attributable to shareholders of 33 million yuan, down 60.83% year-on-year [3]. - The net cash flow from operating activities for 2024 was 21.86 million yuan [3]. Group 3: Fundraising and Use of Proceeds - Longsoft Technology raised a total of 381.93 million yuan from its IPO, with a net amount of 323.63 million yuan after deducting issuance costs [4]. - The intended use of the raised funds includes 48.2 million yuan for a big data cloud service platform project and 89.31 million yuan for a smart mining IoT control platform project [4].

Core Viewpoint - Shenzhen Securities Regulatory Bureau has identified four issues with the company "全新好" related to financial accounting, information disclosure, internal control, and corporate governance [2][6]. Group 1: Financial Accounting Issues - The company failed to consider the impact of rent-free periods in its financial accounting for its rental business from 2022 to 2024 [5]. - Revenue recognition for external sales did not align with disclosure policies and included cross-period situations [5]. - Revenue recognition for the external sales of disinfectant wipes was not compliant with accounting standards [5]. Group 2: Information Disclosure Issues - The company misclassified disinfectant wipes and other daily necessities, leading to incorrect revenue disclosures in the annual reports for 2023 and 2024 [5]. Group 3: Internal Control Issues - The company exhibited inadequate control over its subsidiary, Jiangmen Duheng Paper Technology Co., Ltd., which does not comply with internal control guidelines [5]. Group 4: Corporate Governance Issues - The company failed to sign contracts with some directors and did not timely revise its insider information management system [5]. - There was a lack of proper documentation for insider information personnel, and these individuals did not confirm their records [5]. Group 5: Regulatory Actions - The Shenzhen Securities Regulatory Bureau has mandated corrective measures for the company and issued warning letters to key personnel, including the current and former chairpersons and general managers [7]. - The company is required to submit a written rectification report within 30 days of receiving the regulatory decision [7]. - The company must enhance the professional level of its financial personnel and improve its governance and internal control systems [8].

Core Viewpoint - Shenzhen Securities Regulatory Bureau issued an administrative regulatory decision recognizing four issues with the company, involving financial accounting, information disclosure, internal control, and corporate governance [2][6]. Group 1: Financial Accounting Issues - The company failed to consider the impact of rent-free periods in its financial accounting for its housing leasing business from 2022 to 2024 [7]. - Revenue recognition timing for external sales did not align with disclosure policies and included cross-period situations [7]. - Revenue recognition for the external sales of disinfectant wipes was not compliant with accounting standards [7]. Group 2: Information Disclosure Issues - The company incorrectly classified disinfectant wipes and other daily necessities, leading to errors in revenue disclosure for the years 2023 and 2024 [7]. Group 3: Internal Control Issues - The company exhibited inadequate control over its subsidiary, Jiangmen Duheng Paper Technology Co., Ltd., which does not comply with internal control guidelines [7]. Group 4: Corporate Governance Issues - The company failed to sign contracts with some directors and did not timely revise its insider information management system, leading to non-compliance with regulations [7]. Group 5: Regulatory Measures - The Shenzhen Securities Regulatory Bureau decided to impose corrective measures on the company and issued warning letters to key personnel, including the current and former chairpersons and general managers [9]. - The company is required to submit a written rectification report within 30 days and must enhance the training of its board and senior management on securities laws and regulations [9][10].

Core Viewpoint - The company, Furu Pharmaceutical (300049.SZ), has received a decision from the Inner Mongolia Regulatory Bureau of the China Securities Regulatory Commission, indicating several compliance issues related to internal controls and revenue recognition practices [1][2]. Group 1: Internal Control Issues - The company lacks a comprehensive internal control and risk management system for its important overseas subsidiaries, failing to meet the requirements set forth in the Corporate Governance Guidelines [1]. - Internal departments have not conducted inspections and supervision of overseas subsidiaries, which is also a violation of regulatory standards [1]. Group 2: Revenue Recognition Issues - The company has prematurely recognized revenue from drug sales, resulting in the following overstatements: CNY 2.4089 million for the 2023 semi-annual report, CNY 2.8810 million for the 2023 annual report, CNY 5.6703 million for the 2024 semi-annual report, and CNY 1.3417 million for the 2024 annual report, affecting the accuracy of financial disclosures [2]. - In June 2023, the company fully recognized revenue from a drug sale that included a return clause, but failed to account for the return when it occurred in August, leading to inaccuracies in the 2023 semi-annual report [2]. - The company did not reasonably estimate variable consideration such as sales discounts and rebates in its accounting for 2023 and 2024, resulting in full revenue recognition without appropriate adjustments when discounts were paid [2].

Core Viewpoint - Wuzhou Transportation has received regulatory measures from the Guangxi Securities Regulatory Bureau due to issues related to accounting irregularities and failure to conduct integrity checks on proposed senior management appointments [1][2]. Group 1: Regulatory Actions - The Guangxi Securities Regulatory Bureau issued a corrective order to Wuzhou Transportation for non-compliance with accounting standards and improper revenue recognition practices from 2022 to 2024 [1]. - The company failed to conduct required integrity checks on proposed directors and senior management, violating relevant regulations [1]. Group 2: Company Response - Wuzhou Transportation emphasizes its commitment to addressing the issues raised by the regulatory body and plans to enhance its financial management and compliance practices [2]. - The company will prepare a rectification report within the stipulated timeframe as per the regulatory requirements [2]. Group 3: Business Overview - Wuzhou Transportation is the only listed company in Guangxi operating toll road businesses, with significant operations in toll collection and logistics [3]. - For the first three quarters of 2025, the company reported a revenue of 1.205 billion yuan, a decrease of 0.86% year-on-year, and a net profit of 508 million yuan, down 10.26% year-on-year [3].

Core Viewpoint - Guangdong Marubi Biotechnology Co., Ltd. has been issued an administrative regulatory decision by the Guangdong Securities Regulatory Commission due to irregularities in financial accounting, fundraising management, and disclosure practices [2][4][6]. Financial Accounting Irregularities - The company has been found to have inaccurate revenue accounting, failing to estimate return rates based on actual sales returns and including non-actual sales orders in revenue [4]. - There were inaccuracies in the accounting of construction in progress, with the company not timely estimating unbilled construction payments and failing to transfer assets to fixed assets upon completion [4]. - Errors in accounting classifications were noted, such as misreporting funds held in third-party payment platforms as accounts receivable and misclassifying unrelated consulting fees as research and development expenses [4]. Fundraising Management and Disclosure Issues - The company improperly used fundraising and self-owned funds for the construction of its headquarters without separating the accounting for fundraising projects from non-fundraising projects [5]. - Adjustments to fundraising projects were not timely reviewed and disclosed, leading to discrepancies between reported project progress and actual status [5]. - The company failed to disclose relevant information regarding cash management of fundraising, including returns on financial products and investment details [5]. Regulatory Actions - The chairman, board secretary, and financial director of the company have been held primarily responsible for the violations and have received warning letters from the regulatory authority [6]. Financial Statement Corrections - The company announced corrections to its financial statements for the first half of 2025, revealing inflated figures in various financial metrics, including an increase in operating income by 4.5468 million and net profit by 11.3297 million [7][10]. - The corrected balance sheet showed an overstatement of construction in progress by 568 million and underreported fixed assets and investment properties by 375 million and 183 million, respectively [10]. Recent Financial Performance - For the third quarter of 2025, the company reported operating revenue of 2.45 billion, a year-on-year increase of 25.5%, while net profit attributable to shareholders was 244 million, up 2.1% year-on-year [10].

Core Viewpoint - Beijing Hanjian Heshan Pipeline Co., Ltd. received an administrative supervision measure from the Beijing Securities Regulatory Bureau, requiring the company to rectify issues related to financial accounting, information disclosure, and compliance with regulations [1][2]. Summary by Sections Overall Rectification Arrangement - The company has taken the issues raised in the decision seriously and has communicated them to all board members, supervisors, and senior management. A comprehensive review and analysis of the matters have been conducted, and rectification plans have been proposed [2]. Issues and Measures Ordered for Rectification Issue 1: Non-compliance in Financial Accounting - Problems identified include inaccurate revenue recognition for a project, incorrect write-offs of accounts receivable, and inadequate impairment provisions for construction costs and goodwill [3]. - Rectification measures include holding meetings to approve corrections of prior accounting errors, enhancing financial personnel's understanding of revenue standards, and improving internal controls and audit processes [4][5][6]. Issue 2: Non-compliance in Disclosing Major Litigation - The company failed to timely disclose a cumulative litigation amount of 122 million yuan over 12 months [7]. - Measures taken include establishing a litigation case management system, improving internal communication regarding significant information, and enhancing compliance awareness among management [8][9][10]. Issue 3: Non-compliance in Disclosing Related Transactions - The company did not follow proper procedures for disclosing related transactions totaling 65.63 million yuan over 12 months [11]. - Rectification actions involve confirming related transactions, conducting compliance training, and strengthening internal management regarding related party transactions [12][14][15]. Summary of Rectification Status - The company acknowledges the issues in financial accounting and information disclosure and emphasizes the importance of compliance for sustainable development. It aims to enhance the awareness of regulatory compliance among its management and improve the quality of information disclosure [16].

Core Viewpoint - Beijing Hanjian Heshan Pipeline Co., Ltd. (Hanjian Heshan) has received an administrative regulatory measure from the Beijing Securities Regulatory Bureau due to multiple violations, including improper financial accounting, failure to disclose significant litigation, and non-compliance in disclosing related party transactions [1][2]. Group 1: Regulatory Violations - The company was found to have improper financial accounting practices, including inaccurate revenue recognition for a project in Guangxi, leading to discrepancies in financial statements [1]. - Hanjian Heshan failed to disclose significant litigation, with a total involved amount of 122 million yuan over the past 12 months, and did not report this in its interim report for 2023 [1]. - The company did not properly disclose related party transactions, totaling 65.63 million yuan over the past 12 months, and failed to follow required review procedures and timely information disclosure obligations [1]. Group 2: Regulatory Actions - The Beijing Securities Regulatory Bureau has issued a warning letter to Hanjian Heshan and its key personnel, which will be recorded in the capital market integrity file [2]. - The responsible individuals are required to submit a written rectification report within 15 working days from the receipt of the decision [2]. Group 3: Company Performance - Since August, Hanjian Heshan's stock price has been on a decline, closing at 5.22 yuan per share on September 25, down 1.88% [3].